Tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, is indicated to treat pulmonary arterial hypertension to improve exercise ability.
Patients with group 1 pulmonary hypertension who had a higher pulmonary-systemic pulse pressure ratio had a higher risk for mortality.
Segmental pulmonary hypertension can result from several conditions, such as complex pulmonary atresia, hemitruncus arteriosus, absence/atresia of a single pulmonary artery, and an anomalous pulmonary artery from the aorta feeding a single lung segment.
Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension.
A number of risk factors were associated with chronic thromboembolic pulmonary hypertension, including, age >70 years, female gender, and pulmonary embolism at first venous thromboembolism.
Current research suggests patients with pulmonary arterial hypertension may benefit from iron and vitamin D supplementation.
Patients with World Health Organization Functional Class I pulmonary hypertension experienced a significant reduction in exercise capacity following the shuttle walk test.
Pulmonary hypertension was confirmed by invasive methods in 68% and 47% of patients with and without a measurable tricuspid regurgitation velocity, respectively.
Increased pulmonary pressures, right ventricular dysfunction, and a stiffer pulmonary vascular bed were typical characteristics of early pulmonary vascular disease onset in young adults who were born preterm.
There were no significant differences in pulmonary arterial hypertension survival based on therapy type, age was an important modifier.
Pulmonary arterial stiffness was related to mean pulmonary arterial pressure and heart rate in patients with untreated idiopathic pulmonary arterial hypertension.
The Pediatric Index Pulmonary Hypertension Intensive Care Mortality model was compared with the Pediatric Risk of Mortality 2 and 3 models to determine the best model for predicting mortality.
The fractal dimension of right ventricular trabecular complexity was a good reproducible marker of remodeling in pulmonary hypertension.
Management strategies were discussed for subtypes of PAH-congenital heart disease including Eisenmenger syndrome, PAH with persistent systemic to pulmonary shunts, and PAH with small or coincidental defect or PAH after defect closure.
Cardiopulmonary exercise testing can be an important diagnostic and prognostic tool in pulmonary arterial hypertension.
After iron supplementation, patients with cyanosis experienced significant improvements in hemoglobin concentration, hematocrit, mean corpuscular volume, ferritin, and transferrin saturation
There was no significant difference in efficacy between sildenafil and bosentan initial combination therapy and sildenafil monotherapy in patients with systemic sclerosis-related pulmonary arterial hypertension.
Precapillary pulmonary hypertension and obstructive sleep apnea may be causative factors for central sleep apnea and pulmonary hypertension, respectively.
The variables for the stepwise echocardiographic score included right ventricular systolic pressure, early pulmonary regurgitation gradient, right atrial area size, tricuspid regurgitation velocity, left ventricle eccentricity index, and right ventricle fractional area change.
There was a significant relationship between brain natriuretic peptide levels and mortality in patients with group 1 pulmonary arterial hypertension.
Recent evidence suggests that systemic sclerosis and systemic lupus erythematosus comorbid with pulmonary arterial hypertension should be considered separate diseases.
The 1-year survival rate after lung transplantation in patients with a mean pulmonary arterial pressure ≥25 mm Hg was lower than the survival rate of those with a mean pulmonary arterial pressure <25 mm Hg.
The use of a risk calculator aimed at achieving a low-risk profile in PAH trials is discussed.
Men with higher estradiol and estradiol/testosterone levels had an increased risk for pulmonary arterial hypertension.
Serum chloride was a strong and independent predictor of mortality at 6 months after a pulmonary arterial hypertension diagnosis.
The "egg-and-banana" sign is a valid computed tomography marker of pulmonary hypertension.
A protocolized study including initiation of VA-ECMO may reduce mortality in patients with massive PE.
Ischemic heart disease and kidney dysfunction were identified as 2 comorbidities that may affect outcomes in idiopathic pulmonary arterial hypertension.
Stem cell therapy targeting right ventricular failure may help improve pulmonary circulation in pulmonary arterial hypertension.
The sNDA is accompanied by results from the MERIT-1 trial, a Phase 2 randomized, placebo-controlled, double-blind study which assessed the efficacy, safety and tolerability of macitentan 10mg in 80 patients with inoperable CTEPH.
The Cardiology Advisor Articles
- Class 1 Device Recall: Endologix AFX Device Recalled Due to Type III Endoleaks
- Harvard: Fraudulent Data Found in Publications of Heart Researcher
- Traumatic Life Events May Increase Risk for Atrial Fibrillation in Older Women
- No Differences Between Bivalirudin, UFH Post-PCI After Ticagrelor Pretreatment
- Rivaroxaban Approved to Reduce Risk of Major Cardiovascular Events in CAD, PAD
- Coenzyme Q10 Supplementation May Reduce Statin-Induced Myopathy
- Long-Term Exposure to Elevated BP Associated With AS and AR
- Risk Factors for Atherosclerotic Cardiovascular Disease in the South Asian Population
- Takotsubo Syndrome Associated With Substantial Morbidity, Mortality
- Bariatric Surgery Reduces Macrovascular Complications in Obesity, T2D
- Metformin May Improve Vascular Health in Adolescents With Type 1 Diabetes
- Improved Cardiovascular Event Reporting Needed in Leukemia Clinical Trials
- Psoriasis Associated With Clinical Signs of Accelerated Atherosclerosis
- Can Dermatoscope Magnets Be Used With CV Implanted Electronic Devices?
- The Striking Effects of Diversity in Health Care: Improving Patient Outcomes